drugset / Trial / NCT01595997
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
RandomizedParallel-groupDouble-blindTreatment
Summary
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-08
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DLX105 | Protein / enzyme biologic | 0.02 mg | Other |
| Subject | DLX105 | Protein / enzyme biologic | 1 mg | Other |